- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07596563
Olfactory Cell Transplantation and Intensive Rehabilitation to Repair Chronic Spinal Cord Injury
Safety, Feasibility, Efficacy of Olfactory Cell Transplantation Therapy Combined With Intensive Exercise Rehabilitation to Repair Chronic Traumatic Spinal Cord Injury.
This is a randomised, blinded and controlled Phase I trial to measure the safety, feasibility and efficacy of a combined cell transplantation and intensive rehabilitation intervention to treat spinal cord injury. The trial aims to examine whether transplantation of olfactory cell nerve bridges combined with intensive rehabilitation is safe and feasible for people living with chronic spinal cord injury in Australia, and whether the intervention improves structural integrity of the spinal cord, functional recovery, overall health, and social wellbeing.
For the olfactory cell nerve bridge transplant, cells from inside the patient's own nose will be purified and engrafted as 3D cellular nerve bridges. Participants will receive a dose that is dependent on the size of the accessible space within the injury site of the spinal cord with up to 60 million cells being engrafted. The surgery for the transplantation will be performed by a neurosurgeon in which the spinal cord will be exposed to enable the nerve bridges to be placed into the injury site. The duration of the procedure will be 3-4 hours. Surgical notes will be used to monitor adherence to the protocol.
For intensive exercise rehabilitation, the intervention will be supervised and provided by physiotherapists and exercise physiologists at a for-purpose neurorehabilitation facility. The mode of administration will be one-on-one sessions. The 12- and 32-week rehabilitation programs will consist of up to 3 hours per day at the rehabilitation service providers, for 5 days per week. Participants will attend the provider that is within their geographical area. Over each week, sessions will involve a range and mix of activities which could include, but are not limited to, standing, gait training, upper limb strength, trunk stability/core strength, and aerobic training. Throughout the trial, logs of exercise activities will be completed by the participants and staff at the neurorehabilitation gyms. Rehabilitation will start from day 1 of the priming rehabilitation (PR) program and go for 12 weeks, then surgery and cell transplantation will occur at week 1 of the cell transplantation surgery and recover program which is 2 weeks post conclusion of Priming Rehabilitation (PR), followed by 5 weeks of recovery.
Rehabilitation is for 32 weeks starting 6 weeks post transplant surgery. Regenerative rehabilitation program is from weeks 1-32 of the regenerative rehabilitation (RR) program.
If nerve bridge production fails for whatever reason in the weeks prior to surgery, this will start an extension/contingency/alternative timeline, where a new nasal biopsy will need to be taken from the participant (along with accompanying tests). The cells will be grown up over the next 4 weeks with an additional week of nerve bridge production, while the participant engages in a further five weeks of priming rehabilitation.
Přehled studie
Postavení
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 1
Kontakty a umístění
Studijní kontakt
- Jméno: Andrew Rayfield
- Telefonní číslo: +61(0) 7 5678 0917
- E-mail: scitrial@griffith.edu.au
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion/exclusion criteria for participants have been determined in consultation with medical and rehabilitation specialists including a clinician with lived experience of SCI.
Inclusion Criteria
Participants are eligible to be included in the trial only if all the following criteria apply:
- Have sustained an acquired spinal cord injury a minimum of 4 months prior to consent and have completed their primary rehabilitation;
- Have a stable neurological level and functional ability of more than two months in duration;
- Are over 18 years and able to give informed consent;
- Are AIS A, B or low functioning C (more than 75% of key muscles have a power grade <3) as per the International Standards for Neurological Classification of spinal cord injury, and documented by an ISNCSCI/ASIA exam performed by a qualified practitioner within the last six months;
- Have a thoracic injury or lower cervical (C5-C8) injury;
- Are able and willing to attend an exercise program five times per week for the duration of the priming rehabilitation program, with allowance for two weeks recreational leave;
- Are able and willing to attend an exercise program five times per week for at least 12 weeks of the regenerative rehabilitation program and then at least three days per week for the remaining 20 weeks, with allowance for four weeks recreational leave;
- Are considered by their general practitioner or specialist medical consultant to be fit to receive the cell transplantation and undertake the exercise program (documented approval by general practitioner required).
Exclusion Criteria
Participants are excluded from the trial if any of the following criteria apply:
- Have a high cervical (C1-C4) injury (excluded due to respiratory risk);
- Have significant concomitant central nervous system, peripheral nervous system or musculoskeletal system injuries or disorders limiting their ability to exercise;
- Have had recent major trauma or surgery within the last 4 months;
- Have an existing stage 3 or 4 pressure ulcer according to the National Pressure Ulcer Advisory Panel classification;
- Have endocrinopathy or metabolic disorders of the bone that lead to increased risk of injury from the intense long-term exercise therapy, including but not limited to pathological fractures, Paget's disease, lytic or renal bone disease, and senile osteoporosis;
- Have a medical history of exposure to medication(s) known to adversely affect mineral or bone metabolism;
- Have significant impairment or disability, including physical, neurological or psychological impairments, in addition to the spinal cord injury;
- Have a history of long bone fracture incompletely healed;
- Have extensive fixed contractures in the upper or lower limbs;
- Have severe spasticity that interferes with ability to exercise;
- Have uncontrolled neuropathic pain;
- Have autonomic dysreflexia without a management plan;
- Have a known allergic sensitivity to antibiotics used in the nerve bridge production process;
- Do not have adequate transport options to attend the rehabilitation sessions or the assessments;
- Are unable to attend the pre-intervention assessments and the follow-up assessments;
- Have any contraindications to FES, MRI, X-ray and other study procedures, such as a cardiac pacemaker, epilepsy, lower limb fracture or pregnancy;
- Have any other serious medical condition including but not limited to malignancies, auto-immune disorders (requiring continuous pharmaceutical management), psychiatric, behavioural or drug dependency problems, which are likely to influence the participant's ability to cooperate or, in the opinion of the trial investigator, would prevent adherence to the protocol;
- Have symptomatic, radiologically demonstrated, or provocatively demonstrated ischaemic heart disease;
- Have current thromboembolic disease;
- Are using illicit drugs;
- Are participating in other clinical trials (including medication, therapeutic interventions and alternative therapies).
- Are unable to tolerate expected exercise load.
- Are unable to comply with the assessment regime (such as having claustrophobia which prevents MRI procedures being conducted);
- Are unable to demonstrate that they have adequate social/family/carer support at home to enable their participation throughout the trial.
- Evidence of an active infection, confirmed by testing, of a type that would pose an unacceptable risk for the viability of the nasal biopsy, the cell production, or the nerve bridge production.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: Treatment group of cell and rehabilitation
20 participants will be recruited
|
Treatment group of cell transplantation and rehabilitation
|
|
Aktivní komparátor: Control Rehabilitation only group
10 participants will be recruited
|
control rehabilitation only group
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Recruitment feasibility. Feasibility of delivering a cell therapy intervention and associated rehabilitation program in terms of recruitment rate - i.e. willingness of participants to complete the full program. This is a composite primary outcome.
Časové okno: 3 weeks after completion of full intervention (Regenerative Rehab (RR) week 32 of Regenerative Rehabilitation Program) i.e. at RR week 35 (post commencement of Regenerative Rehabilitation Program)
|
3 weeks after completion of full intervention (Regenerative Rehab (RR) week 32 of Regenerative Rehabilitation Program) i.e. at RR week 35 (post commencement of Regenerative Rehabilitation Program)
|
|
Safety Ratings. This Outcome and assessment is of safety in general, so it encompasses all AEs and SAEs and so is a composite primary outcome.
Časové okno: 3 weeks after completion of full intervention (Regenerative Rehab (RR) week 32 of Regenerative Rehabilitation Program) i.e. at RR week 35 (post commencement of Regenerative Rehabilitation Program)
|
3 weeks after completion of full intervention (Regenerative Rehab (RR) week 32 of Regenerative Rehabilitation Program) i.e. at RR week 35 (post commencement of Regenerative Rehabilitation Program)
|
|
Safety of transplantation: measured by adverse anatomical changes to the injury/transplant site using quantitative MRI measures.
Časové okno: MRI/FA-DTI measured at week 0 (the week prior to start of priming rehab (PR)), week 13 of PR, at week 0 of regenerative rehab (RR), RR week 7, RR week 20, RR week 33.
|
MRI/FA-DTI measured at week 0 (the week prior to start of priming rehab (PR)), week 13 of PR, at week 0 of regenerative rehab (RR), RR week 7, RR week 20, RR week 33.
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
4a. Changes in AIS grade
Časové okno: Outcome measured at screening, then week Priming Rehabilitation (PR) week 13, Regenerative Rehab(RR) week 7, RR week 20, RR week 33 (i.e. 33 weeks post-commencement of Regenerative Rehabilitation intervention
|
Outcome measured at screening, then week Priming Rehabilitation (PR) week 13, Regenerative Rehab(RR) week 7, RR week 20, RR week 33 (i.e. 33 weeks post-commencement of Regenerative Rehabilitation intervention
|
|
|
Changes in electrophysiological assessments - somatosensory evoked potentials (SSEP)
Časové okno: Outcome measured at priming rehab (PR) week 0, PR week 13, a week later at transplant week 1 (SSEP during surgery), Regenerative Rehab (RR) week 0, RR week 33)
|
Outcome measured at priming rehab (PR) week 0, PR week 13, a week later at transplant week 1 (SSEP during surgery), Regenerative Rehab (RR) week 0, RR week 33)
|
|
|
Changes in biomarkers (CSF): Thousands of protein biomarkers will be assessed from the one sample. Examples of biomarkers of interest include markers for inflammation and neural injury.
Časové okno: Outcome measured at baseline (post screening), then Transplant Surgery (TS) week 4) and Regenerative Rehab (RR) week 33, i.e. 33 weeks post-commencement of Regenerative rehab intervention.
|
Outcome measured at baseline (post screening), then Transplant Surgery (TS) week 4) and Regenerative Rehab (RR) week 33, i.e. 33 weeks post-commencement of Regenerative rehab intervention.
|
|
|
Changes in biomarkers (Serum). Thousands of protein biomarkers will be assessed from the one sample. Examples of biomarkers of interest include markers for inflammation and neural injury.
Časové okno: Outcome measured at baseline (post-screening), then Priming Rehabilitation (PR) week 13, Transplant Surgery (TS) week 4, Regenerative Rehab (RR) week 0, RR week 20, RR week 33 post-commencement of regenerative rehab intervention.
|
Outcome measured at baseline (post-screening), then Priming Rehabilitation (PR) week 13, Transplant Surgery (TS) week 4, Regenerative Rehab (RR) week 0, RR week 20, RR week 33 post-commencement of regenerative rehab intervention.
|
|
|
8a. Changes in vital signs - Body temperature. All vital signs will be assessed as a composite secondary outcome.
Časové okno: Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
|
|
Pulmonary Function (Spirometry)
Časové okno: Outcome measured at screening, Priming Rehabilitation (PR) week 0 (for those who have had metal work removal surgery prior), PR week 13, Regenerative Rehab (RR) week 0, RR week 33 (33 weeks post commencement of regenerative rehab) intervention
|
9a. Forced Expiratory Volume in 1 Second
|
Outcome measured at screening, Priming Rehabilitation (PR) week 0 (for those who have had metal work removal surgery prior), PR week 13, Regenerative Rehab (RR) week 0, RR week 33 (33 weeks post commencement of regenerative rehab) intervention
|
|
Bone Mineral Density (DEXA)
Časové okno: Outcome measured at screening, then Priming Rehabilitation (PR) week 13, Regenerative Rehabilitation (RR) week 33 post-commencement of Regenerative Rehab intervention
|
10b. T score
|
Outcome measured at screening, then Priming Rehabilitation (PR) week 13, Regenerative Rehabilitation (RR) week 33 post-commencement of Regenerative Rehab intervention
|
|
Full Blood Count (FBC)
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11e. White Blood Cell Count
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Motor Function
Časové okno: Outcome measured at screening, then Priming Rehabilitation (PR) week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32, post commencement of Regenerative Rehab intervention.
|
12a. Manual Muscle Testing Score
|
Outcome measured at screening, then Priming Rehabilitation (PR) week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32, post commencement of Regenerative Rehab intervention.
|
|
Muscle Strength (5 RM)
Časové okno: Outcome measured at screening, then Priming Rehabilitation (PR) week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32, post commencement of Regenerative Rehab intervention.
|
13a. Upper Limb Strength
|
Outcome measured at screening, then Priming Rehabilitation (PR) week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32, post commencement of Regenerative Rehab intervention.
|
|
Pain
Časové okno: Outcome measured at screening, then Priming Rehabilitation (PR) week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32, post commencement of Regenerative Rehab intervention.
|
14a. Pain Severity
|
Outcome measured at screening, then Priming Rehabilitation (PR) week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32, post commencement of Regenerative Rehab intervention.
|
|
Cardiovascular function
Časové okno: Outcome measured at screening, then Priming Rehabilitation (PR) week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32, post commencement of Regenerative Rehab intervention
|
15a. Arm Ergometry Exercise Duration
|
Outcome measured at screening, then Priming Rehabilitation (PR) week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32, post commencement of Regenerative Rehab intervention
|
|
Bowel, bladder function and independence
Časové okno: Outcome measured at screening, then Priming Rehabilitation (PR) week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32, post commencement of Regenerative Rehab intervention.
|
16a. Functional Independence Score
|
Outcome measured at screening, then Priming Rehabilitation (PR) week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32, post commencement of Regenerative Rehab intervention.
|
|
Fatigue
Časové okno: Outcome measured at screening, then Priming Rehabilitation (PR)week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32 and RR week 35 (End of Study week) i.e. post commencement of Regenerative Rehab intervention.
|
17a. Fatigue Severity
|
Outcome measured at screening, then Priming Rehabilitation (PR)week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32 and RR week 35 (End of Study week) i.e. post commencement of Regenerative Rehab intervention.
|
|
Depression, Anxiety and Stress
Časové okno: Outcome measured at screening, then Priming Rehabilitation (PR)week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32 and RR week 35 (End of Study week) i.e. post commencement of Regenerative Rehab intervention.
|
18a. Depression Score
|
Outcome measured at screening, then Priming Rehabilitation (PR)week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32 and RR week 35 (End of Study week) i.e. post commencement of Regenerative Rehab intervention.
|
|
Quality of Life
Časové okno: Outcome measured at screening, then Priming Rehabilitation (PR) week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32 and RR week 35 (End of Study week) i.e. post commencement of Regenerative Rehab intervention
|
19a. Health Utility Index
|
Outcome measured at screening, then Priming Rehabilitation (PR) week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32 and RR week 35 (End of Study week) i.e. post commencement of Regenerative Rehab intervention
|
|
Suicidal ideation and behaviour.
Časové okno: Outcome measured at screening, then Priming Rehabilitation (PR)week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32 and RR week 35 (End of Study week) i.e. post commencement of Regenerative Rehab intervention.
|
20a. Suicidality Severity
|
Outcome measured at screening, then Priming Rehabilitation (PR)week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32 and RR week 35 (End of Study week) i.e. post commencement of Regenerative Rehab intervention.
|
|
Muscle tone
Časové okno: Outcome measured at screening, then Priming Rehabilitation (PR) week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32, post commencement of Regenerative Rehab intervention.
|
21a. Spasticity Severity
|
Outcome measured at screening, then Priming Rehabilitation (PR) week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32, post commencement of Regenerative Rehab intervention.
|
|
Lived experience
Časové okno: Outcome measured at baseline, Priming Rehabilitation (PR) week 13, Regenerative Rehab (RR) week 9, RR week 35 (i.e. 35 weeks post commencement of Regenerative Rehab intervention.)
|
22a. Participant Experience Themes
|
Outcome measured at baseline, Priming Rehabilitation (PR) week 13, Regenerative Rehab (RR) week 9, RR week 35 (i.e. 35 weeks post commencement of Regenerative Rehab intervention.)
|
|
Feasibility of transplantation assessed by clinician-developed questionnaire with discrete parameters and medical surgical notes. Will report success or difficulties of nerve bridge transplantation procedure.
Časové okno: 3 weeks after completion of Regenerative Rehab (RR) intervention (RR week 32) at RR week 35 (Final study/End of study week).
|
3 weeks after completion of Regenerative Rehab (RR) intervention (RR week 32) at RR week 35 (Final study/End of study week).
|
|
|
Feasibility of delivery of rehabilitation and assessments.
Časové okno: 3 weeks after completion of Regenerative Rehab (RR) intervention (RR week 32) at RR week 35 (Final study/End of study week).
|
24a. Assessment Completion Rate
|
3 weeks after completion of Regenerative Rehab (RR) intervention (RR week 32) at RR week 35 (Final study/End of study week).
|
|
Changes in electrophysiological assessments - Motor Evoked Potentials (MEP)
Časové okno: Outcome measured at priming rehab (PR) week 0, PR week 13, a week later at transplant week 1 (MEP during surgery), Regenerative Rehab (RR) week 0, RR week 33)
|
Outcome measured at priming rehab (PR) week 0, PR week 13, a week later at transplant week 1 (MEP during surgery), Regenerative Rehab (RR) week 0, RR week 33)
|
|
|
Blood and serum tests: Coagulation studies
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
|
Blood and serum tests: Blood Sugar Tests
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
|
Blood and serum tests: Serological tests (test for HIV I/II, HTLV I/II, HBSAg, HBCAb, Syphilis serology)
Časové okno: Outcome measured at screening, again at Baseline. If nerve bridge fails an new biopsy needed, serology test again at Priming Rehab (PR) week 14, before biopsy taken.
|
Outcome measured at screening, again at Baseline. If nerve bridge fails an new biopsy needed, serology test again at Priming Rehab (PR) week 14, before biopsy taken.
|
|
|
Blood and serum tests: Liver function tests
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
|
Blood and serum tests: Lipid profile
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
|
Blood and serum tests: Brain natriuretic peptide (BNP)
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
|
Blood and serum tests: Chem20 panel
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
|
Acceptability of the program
Časové okno: At the end of the priming rehabilitation (PR) program: PR week 13 and at the final week of the regenerative rehabilitation (RR): RR week 35.
|
33a. Retention Rate
|
At the end of the priming rehabilitation (PR) program: PR week 13 and at the final week of the regenerative rehabilitation (RR): RR week 35.
|
|
Quantitative MRI and DTI -Anatomical Repair
Časové okno: MRI/FA-DTI measured at week 0, Priming Rehab (PR) week 13, week 0 of regenerative rehab (RR), RR week 7, RR week 20, RR week 33
|
34a. Spinal Cord Cross Sectional Area
|
MRI/FA-DTI measured at week 0, Priming Rehab (PR) week 13, week 0 of regenerative rehab (RR), RR week 7, RR week 20, RR week 33
|
|
Exploratory rs fMRI - Functional Connectivity
Časové okno: rs-fMRI measured at week 0, Priming Rehab (PR) week 13, Regenerative rehab (RR) week 0, RR week 7, RR week 20, RR week 33.
|
35a. Functional Connectivity Strength
|
rs-fMRI measured at week 0, Priming Rehab (PR) week 13, Regenerative rehab (RR) week 0, RR week 7, RR week 20, RR week 33.
|
|
Exploratory Safety - rs fMRI Signal Stability)
Časové okno: rs-fMRI measured at week 0, Priming Rehab (PR) week 13, Regenerative Rehab (RR) week 0, RR week 7, RR, week 20, RR week 33.
|
36a. Temporal Signal to Noise Ratio
|
rs-fMRI measured at week 0, Priming Rehab (PR) week 13, Regenerative Rehab (RR) week 0, RR week 7, RR, week 20, RR week 33.
|
|
Bladder Function
Časové okno: Outcome measured at Baseline then Priming Rehabilitation (PR) week 13, and Regenerative Rehabilitation (RR) week 33 (i.e. 33 weeks post commencement of regenerative rehabilitation intervention.)
|
37a. Bladder Pressure
|
Outcome measured at Baseline then Priming Rehabilitation (PR) week 13, and Regenerative Rehabilitation (RR) week 33 (i.e. 33 weeks post commencement of regenerative rehabilitation intervention.)
|
|
Changes in AIS grade, total sensory score, and total motor score
Časové okno: Outcome measured at screening, then week Priming Rehabilitation (PR) week 13, Regenerative Rehab(RR) week 7, RR week 20, RR week 33 (i.e. 33 weeks post-commencement of Regenerative Rehabilitation intervention
|
Outcome measured at screening, then week Priming Rehabilitation (PR) week 13, Regenerative Rehab(RR) week 7, RR week 20, RR week 33 (i.e. 33 weeks post-commencement of Regenerative Rehabilitation intervention
|
|
|
4b. Changes in AIS total sensory score
Časové okno: Outcome measured at screening, then week Priming Rehabilitation (PR) week 13, Regenerative Rehab(RR) week 7, RR week 20, RR week 33 (i.e. 33 weeks post-commencement of Regenerative Rehabilitation intervention
|
Outcome measured at screening, then week Priming Rehabilitation (PR) week 13, Regenerative Rehab(RR) week 7, RR week 20, RR week 33 (i.e. 33 weeks post-commencement of Regenerative Rehabilitation intervention
|
|
|
4c. Changes in AIS total motor score
Časové okno: Outcome measured at screening, then week Priming Rehabilitation (PR) week 13, Regenerative Rehab(RR) week 7, RR week 20, RR week 33 (i.e. 33 weeks post-commencement of Regenerative Rehabilitation intervention
|
Outcome measured at screening, then week Priming Rehabilitation (PR) week 13, Regenerative Rehab(RR) week 7, RR week 20, RR week 33 (i.e. 33 weeks post-commencement of Regenerative Rehabilitation intervention
|
|
|
8b. Changes in vital signs- blood pressure. All vital signs will be assessed as a composite secondary outcome.
Časové okno: Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
|
|
8c. Changes in vital signs - heart rate. All vital signs will be assessed as a composite secondary outcome.
Časové okno: Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
|
|
8d. Changes in vital signs- respiratory rate. All vital signs will be assessed as a composite secondary outcome.
Časové okno: Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
|
|
8e. Changes in vital signs- oxygen saturation. All vital signs will be assessed as a composite secondary outcome.
Časové okno: Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
|
|
8f. Electrical Activity of the Heart (Electrocardiography)
Časové okno: Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
8f- 3. PR Interval
|
Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
|
White Blood Cell Differential (Absolute Counts)
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11g. Neutrophil Count
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Reticulocytes and Red Cell Indices
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11l. Reticulocyte Count
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Inflammation Markers
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11n. C Reactive Protein
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Coagulation Studies
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11q. Prothrombin Time
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Metabolic and Biochemistry Panel (E/LFT Panel - MB2)
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11s. Serum Sodium
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Metabolic and Biochemistry Panel (E/LFT Panel - MB2)
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11z. Serum Creatinine
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Liver Function Tests
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11ab. Alanine Aminotransferase
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Liver Function Tests
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11ah. Total Protein
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Lipid Profile
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11aj. Total Cholesterol
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Glycaemic Markers
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11an. Fasting Serum Glucose
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Cardiac Biomarker
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11ap. NT proBNP
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Infectious Disease Serology
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11aq. Hepatitis B Surface Antigen
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Microbiological Testing
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11av. Genital / Urethral Swab Culture
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
9. Pulmonary Function (Spirometry)
Časové okno: Outcome measured at screening, Priming Rehabilitation (PR) week 0 (for those who have had metal work removal surgery prior), PR week 13, Regenerative Rehab (RR) week 0, RR week 33 (33 weeks post commencement of regenerative rehab) intervention
|
9c. FEV1/FVC Ratio
|
Outcome measured at screening, Priming Rehabilitation (PR) week 0 (for those who have had metal work removal surgery prior), PR week 13, Regenerative Rehab (RR) week 0, RR week 33 (33 weeks post commencement of regenerative rehab) intervention
|
|
10. Bone Mineral Density (DEXA)
Časové okno: Outcome measured at screening, then Priming Rehabilitation (PR) week 13, Regenerative Rehabilitation (RR) week 33 post-commencement of Regenerative Rehab intervention
|
10a. Areal Bone Mineral Density
|
Outcome measured at screening, then Priming Rehabilitation (PR) week 13, Regenerative Rehabilitation (RR) week 33 post-commencement of Regenerative Rehab intervention
|
|
Full Blood Count (FBC)
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11a. Hemoglobin
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Full Blood Count (FBC)
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11b. Hematocrit
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Full Blood Count (FBC)
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11c. Red Blood Cell Count
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Full Blood Count (FBC)
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11d. Mean Corpuscular Volume
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Motor Function
Časové okno: Outcome measured at screening, then Priming Rehabilitation (PR) week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32, post commencement of Regenerative Rehab intervention.
|
12b. Six Minute Walk / Push Distance
|
Outcome measured at screening, then Priming Rehabilitation (PR) week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32, post commencement of Regenerative Rehab intervention.
|
|
Cardiovascular function
Časové okno: Outcome measured at screening, then Priming Rehabilitation (PR) week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32, post commencement of Regenerative Rehab intervention
|
15b. Heart Rate Response
|
Outcome measured at screening, then Priming Rehabilitation (PR) week 1, PR week 7, PR week 12, Regenerative Rehab (RR) week 1, RR week 12, RR week 24, RR week 32, post commencement of Regenerative Rehab intervention
|
|
Quantitative MRI and DTI -Anatomical Repair
Časové okno: MRI/FA-DTI measured at week 0, Priming Rehab (PR) week 13, week 0 of regenerative rehab (RR), RR week 7, RR week 20, RR week 33
|
34b. Fractional Anisotropy
|
MRI/FA-DTI measured at week 0, Priming Rehab (PR) week 13, week 0 of regenerative rehab (RR), RR week 7, RR week 20, RR week 33
|
|
Quantitative MRI and DTI -Anatomical Repair
Časové okno: MRI/FA-DTI measured at week 0, Priming Rehab (PR) week 13, week 0 of regenerative rehab (RR), RR week 7, RR week 20, RR week 33
|
34c. Mean Diffusivity
|
MRI/FA-DTI measured at week 0, Priming Rehab (PR) week 13, week 0 of regenerative rehab (RR), RR week 7, RR week 20, RR week 33
|
|
Bladder Function
Časové okno: Outcome measured at Baseline then Priming Rehabilitation (PR) week 13, and Regenerative Rehabilitation (RR) week 33 (i.e. 33 weeks post commencement of regenerative rehabilitation intervention.)
|
37b. Bladder Volume
|
Outcome measured at Baseline then Priming Rehabilitation (PR) week 13, and Regenerative Rehabilitation (RR) week 33 (i.e. 33 weeks post commencement of regenerative rehabilitation intervention.)
|
|
Reticulocytes and Red Cell Indices
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11m. Mean Corpuscular Hemoglobin Concentration
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Inflammation Markers
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11o. Erythrocyte Sedimentation Rate
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Coagulation Studies
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11p. International Normalised Ratio
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Metabolic and Biochemistry Panel (E/LFT Panel - MB2)
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Liver Function Tests
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11af. Total Bilirubin
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Glycaemic Markers
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11ao. HbA1c
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
8f. Electrical Activity of the Heart (Electrocardiography)
Časové okno: Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
8f -1. Heart Rhythm
|
Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
|
8f. Electrical Activity of the Heart (Electrocardiography)
Časové okno: Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
8f- 2. Heart Rate on ECG
|
Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
|
8f. Electrical Activity of the Heart (Electrocardiography)
Časové okno: Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
8f- 6. ST Segment Abnormalities
|
Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
|
Infectious Disease Serology
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11ar. Hepatitis C Antibody
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Infectious Disease Serology
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11as. Human Immunodeficiency Virus
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Infectious Disease Serology
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11at. Human T Lymphotropic Virus
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
Infectious Disease Serology
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11au. Syphilis Serology
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
9. Pulmonary Function (Spirometry)
Časové okno: Outcome measured at screening, Priming Rehabilitation (PR) week 0 (for those who have had metal work removal surgery prior), PR week 13, Regenerative Rehab (RR) week 0, RR week 33 (33 weeks post commencement of regenerative rehab) intervention
|
9b. Forced Vital Capacity
|
Outcome measured at screening, Priming Rehabilitation (PR) week 0 (for those who have had metal work removal surgery prior), PR week 13, Regenerative Rehab (RR) week 0, RR week 33 (33 weeks post commencement of regenerative rehab) intervention
|
|
Bone Mineral Density (DEXA)
Časové okno: Outcome measured at screening, then Priming Rehabilitation (PR) week 13, Regenerative Rehabilitation (RR) week 33 post-commencement of Regenerative Rehab intervention
|
10c. Z score
|
Outcome measured at screening, then Priming Rehabilitation (PR) week 13, Regenerative Rehabilitation (RR) week 33 post-commencement of Regenerative Rehab intervention
|
|
Full Blood Count (FBC)
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11f. Platelet Count
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
|
8f. Electrical Activity of the Heart (Electrocardiography)
Časové okno: Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
8f -4. QRS Duration
|
Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
|
8f. Electrical Activity of the Heart (Electrocardiography)
Časové okno: Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
8f-5. QT Interval (Corrected)
|
Outcome measured at screening, then week 1, week 7, week 12, week 17 and week 48 (post-intervention commencement). ECG monitoring will be done on week 12 as a pre-operative check up.
|
|
Coagulation Studies
Časové okno: Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
11r. Activated Partial Thromboplastin Time
|
Outcome measured at screening, then Priming Rehabilitaton (PR) week 13, Transplant Surgery (TS) week 4), Regenerative Rehab (RR) week 0, RR week 20, RR week 33, i.e. 33 weeks post commencement of regenerative rehab intervention.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Brent McMonagle, Dr, Gold Coast University Hospital
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- GUSIP03
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
- ANALYTIC_CODE
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Poranění míchy
-
Assiut UniversityDokončeno
-
University of Sao PauloZatím nenabírámeOtok | Varixy; CordBrazílie
-
Qianfoshan HospitalChinese Medical AssociationNábor
-
Tel-Aviv Sourasky Medical CenterNeznámýOprava kraniosynostózy | Untethering of Cord
-
National University of MalaysiaMalaysia Automotive Robotics and Innovation of Technology InstituteDokončenoProtilátka | Vakcína | Mateřský | CordMalajsie
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)NáborTransplantace hematopoetických kmenových buněk | Transplantace kmenových buněk z pupečníkové krve | Transplantace pupečníkové krveSpojené státy
-
University of Southern CaliforniaDokončenoDysfonie | Atrofie hlasivek | Presbylarynx | Atrofie; Hrtan | Presbylarynges | Jizva vokálních záhybů | Sulcus Vocalis z Vocal CordSpojené státy